


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number:	WO 96/22277
C07C 275/32, 271/54, 219/34, 271/28, A61K 31/17, 31/27		(43) International Publication Date:	25 July 1996 (25.07.96)
(21) International Application Number:	PCT/GB96/00112	(81) Designated States:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	19 January 1996 (19.01.96)	Published	With international search report.
(30) Priority Data:	9501052.6 19 January 1995 (19.01.95) GB		
(71) Applicant (for all designated States except US):	CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED [GB/GB]; 6-10 Cambridge Terrace, Regent's Park, London NW1 4JL (GB).		
(72) Inventors; and			
(73) Inventors/Applicants (for US only):	SPRINGER, Caroline, Joy [GB/GB]; The Institute of Cancer Research, The Royal Marsden Hospital, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 2NG (GB). NICULESCU-DUVAZ, Ion [RO/GB]; The Institute of Cancer Research, The Royal Marsden Hospital, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 2NG (GB).		
(74) Agents:	BRASNETT, Adrian, Hugh et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		

(54) Title: NITROGEN MUSTARD PRODRUGS WITH NOVEL LIOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION



(57) Abstract

The invention provides compounds of formula (I) and (II) wherein X and Y are independently chlorine, bromine, iodine, a mesyl group CH_3SO_3 or a tosyl group $\text{OSO}_2\text{phenyl}$ (wherein phenyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from $\text{C}_1\text{-alkyl}$, halogen, cyano or nitro; R^1 and R^2 are independently 1 to 4 optional substituents; Z^1 and Z^2 are each independently -O- or -NH-; R^3 is hydrogen, t -butyl or allyl; Z^3 is a hydrocarbyl group such as carboxyethyl, optionally containing heteroatoms, and physiologically acceptable derivatives thereof. The compounds can be converted *in situ* into nitrogen mustard agents by the actions of enzymes such as carboxypeptidase or nitroreductase and are useful for the treatment of cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING
GROUPS, AND PROCESSES FOR THEIR PRODUCTION**


The present invention relates to prodrugs and their use in the treatment of disease, including cancers.

The use of prodrugs represents a clinically very valuable concept in cancer therapy since, particularly where the prodrug is to be converted to an anti-tumour agent under the influence 5 of an enzyme that is linkable to a monoclonal antibody that will bind to a tumour associated antigen, the combination of such a prodrug with such an enzyme monoclonal/antibody conjugate represents a very powerful clinical agent. This approach to cancer therapy, often referred to as "antibody directed enzyme/prodrug therapy" (ADEPT) is disclosed in WO88/07378.

10 More recently, a similar approach ("GDEPT", Gene-Directed Enzyme Prodrug Therapy) has been proposed where in place of an antibody/enzyme conjugate, tumour cells are targeted with a viral vector carrying a gene encoding an enzyme capable of activating a prodrug. The gene may be transcriptionally regulated by tumour specific promoter or enhancer sequences. The viral vector enters tumour cells and expresses the enzyme, in order that a prodrug is 15 converted to an active drug only in the vicinity of the tumour cells (Huber et al. Proc. Natl. Acad. Sci. USA (1991) 88, 8039). The enzyme may be targeted to particular subcellular locations or expressed at the cell surface.

The present invention provides novel prodrugs which contain protecting groups which are more lipophilic than compounds of the prior art such as those disclosed in WO88/07378.

20 Accordingly, the present invention provides compounds of the formula (I):



wherein X and Y are independently chlorine, bromine, iodine, a mesyl group CH_3SO_3 , or a tosyl group $\text{OSO}_2\text{phenyl}$ (wherein phenyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from C_{1-4} alkyl, halogen, cyano or nitro);

n is an integer from 0 to 4 and each group R^1 , which may be the same or different when n is greater than 1, is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C_{1-4} alkyl optionally containing one double bond or one triple bond, C_{1-4} alkoxy, $-\text{CONR}^7\text{R}^8$ (wherein R^7 and R^8 are as defined below), $-\text{NH}(\text{C}_{1-4}\text{-alkyl})$, $-\text{N}(\text{C}_{1-4}\text{-alkyl})_2$ or C_{2-5} alkanoyl; or when n is 2 or more and two groups R^1 are on adjacent positions on the phenylene ring, 2 adjacent R^1 groups together represent

10 a) C_4 alkylene optionally having one double bond;
 b) C_3 alkylene; or
 c) $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}_2-$, or $-\text{CH}_2-\text{CH}=\text{CH}-$ each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, halogen, cyano, nitro, C_{2-5} alkanoyl and $-\text{CONR}^7\text{R}^8$ (wherein R7 and R8 are as defined below);

15 m is an integer from 0 to 4 and R^2 , which may be the same or different when m is greater than 1, is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C_{1-4} alkyl optionally containing one double bond or one triple bond, C_{1-4} alkoxy, $-\text{CONR}^7\text{R}^8$ (wherein R^7 and R^8 are as defined below), $-\text{NH}(\text{C}_{1-4}\text{-alkyl})$, $-\text{N}(\text{C}_{1-4}\text{-alkyl})_2$ and C_{2-5} alkanoyl; or when n is 2 or more and two groups R^1 are on adjacent positions on the phenylene ring, 2 adjacent R^1 groups together represent

20 a) C_4 alkylene optionally having one double bond;
 b) C_3 alkylene; or

c) $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}_2-$ or $-\text{CH}_2-\text{CH}=\text{CH}-$ each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, halogen, cyano, nitro, C_{2-5} alkanoyl and $-\text{CONR}7\text{R}8$ (wherein R7 and R8 are as defined below);

5 Z^1 and Z^2 are each independently $-\text{O}-$ or $-\text{NH}-$;

R^3 is hydrogen, β -butyl or allyl;

Z^3 is a group $-\text{V}-\text{W}$ where V is $-\text{CH}_2-\text{T}-$ in which T is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$, $-(\text{SO})-$ or $-(\text{SO}_2)-$ (provided that when V has sulphur or oxygen as its second atom, W is other than $-\text{COOH}$) and said group V optionally further carrying one or two substituents Q1 and/or Q2 on carbon;

10 wherein Q¹ and Q² each independently represents C_{1-4} alkyl or halogen; or, when Q1 and Q2 are bonded to adjacent carbon atoms, Q¹ and Q² together may additionally represent a $\text{C}_1\text{-}\text{C}_4$ alkylene radical optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of C_{1-4} alkyl and halogen; and W represents

15 (1) COOH,

 (2) $-(\text{C}=\text{O})-\text{O}-\text{R}6$ wherein R6 represents a C_{1-6} alkyl, C_{3-6} cycloalkyl or aryl (as defined in 3 below) group;

 (3) $-(\text{C}=\text{O})-\text{NR}7\text{R}8$ wherein R7 and R8 each independently represent hydrogen or a C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl linked to N via carbon or C_{7-9} aralkyl group wherein

20 aryl is phenyl;

 heteroaryl is a 5 or 6 membered ring containing 1 to 3 heteroatoms selected from the group consisting of nitrogen and sulphur;

 the aryl moiety *per se*, the heteroaryl moiety and the aryl moiety of the aralkyl group may be substituted on carbon with 1-4 substituents selected from the group consisting of $-\text{COOH}$, $-\text{OH}$, $-\text{NH}_2$, $-\text{CH}_2-\text{NH}_2$, $-(\text{CH}_2)_{1-4}\text{-COOH}$, tetrazol-5-yl and $-\text{SO}_3\text{H}$ and the alkyl moiety may optionally carry a methyl group;

25 (4) $-\text{SO}_2\text{NHR}9$ wherein R9 is as defined for R7 but may additionally represent $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$ or aryl as defined above;

 (5) $\text{SO}_2\text{R}10$ in which R10 represents H, C_{1-6} alkyl or C_{3-6} cycloalkyl.

30 (6) $\text{PO}_3\text{R}10\text{R}10$ (wherein the R10 radicals, which may be the same or different, are as herein defined)

 (7) a tetrazol-5-yl group:

(8) -CONH-SO₂R11 in which R11 represents

- (a) C₃₋₇ cycloalkyl;
- (b) C₁₋₆-alkyl optionally substituted with substituents selected from the group consisting of aryl as defined below, C₁₋₄-alkyl, CF₃ or halogen; and
- (c) perfluoro-C₁₋₆ alkyl; wherein
aryl is phenyl or phenyl having 1-5 substituents wherein the substituents are selected from the group consisting of halogen, -NO₂, -CF₃, C₁₋₄ alkyl, C₁₋₄ alkoxy, -NH₂, -NHCOPH₃, -CONH₂, -OCH₂COOH, -NH(C₁₋₄-alkyl), -N(C₁₋₄-alkyl)₂, -NHCOOC₁₋₄ alkyl, -OH, -COOH, -CN and -COOC₁₋₄ alkyl; and

10 (9) -M-Het wherein M represents S, SO or SO₂ and Het represents a 5 or 6 membered heterocyclic aromatic ring linked to M via a carbon atom of the aromatic ring, said aromatic ring containing 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S said aromatic ring optionally being substituted on carbon atoms of the ring with 1, 2, 3 or 4 substituents selected from the group consisting of -OH, -SH, -CN, -CF₃, NH₂ and halogen;

15 and physiologically acceptable derivatives of the compound of formula (I).

These prodrugs can be activated at the site of a tumour by a carboxypeptidase enzyme, for example, CPG2 as disclosed in WO88/07378 or WO94/02450. The carboxypeptidase enzyme may be delivered to the site of a tumour by a GDEPT system as described in the prior art.

20 A carboxypeptidase enzyme is capable of removing the glutamic acid or glutamic acid-derivative moiety (which are preferably in the L-configuration) of compounds of the formula (I). While not wishing to be bound by any one particular theory, it is believed the removal of the glutamic acid moiety from the compounds produces an unstable intermediate compound which undergoes self-immolation to remove the 4-amino or 4-hydroxyl-benzylic system

25 (situated between the groups Z¹ and Z²) thus leading to the release of the alkylating nitrogen mustard drug.

CPG enzyme is available from Sigma Chemical Company, Fancy Road, Poole, Dorset, U.K. CPG enzyme was described in: Goldman, P. and Levy, C.C., PNAS USA, 58: 1299-1306 (1967) and in: Levy, C.C. and Goldman P., J. Biol. Chem., 242: 2933-2938 (1967).


30 Carboxypeptidase G3 enzyme has been described in Yasuda, N. et al., Biosci. Biotech.

Biochem., 56: 1536-1540 (1992). Carboxypeptidase G2 enzyme has also been described in European Patent 121 352.

Large scale purification of CPG2 from Pseudomonas RS-16 was described in Sherwood *et al.* (1985), Eur. J. Biochem., 148, 447-453.

CPG2 may also be obtained by recombinant techniques. The nucleotide coding sequence for CPG2 has been published by Minton, N.P. *et al.*, Gene, 31 (1984), 31-38. Expression of the coding sequence has been reported in *E.coli* (Chambers, S.P. *et al.*, Appl. Microbiol. Biotechnol. (1988), 29, 572-578) and in Saccharomyces cerevisiae (Clarke, L. E. *et al.*, J. Gen Microbiol, (1985) 131, 897-904). Total gene synthesis has been described by M. Edwards in Am. Biotech. Lab (1987), 5, 38-44.

The present invention further provides nitrogen mustard prodrugs of the formula (II):



wherein X, Y, R¹, n, Z¹, R² and m are as defined for compounds of the formula (I), and physiologically acceptable derivatives thereof.

These prodrugs can be activated at the site of a tumour by a nitroreductase enzyme, for example, as disclosed in WO93/08288. The nitroreductase enzyme may be delivered to the site of a tumour by a GDEPT system as described in the prior art.

Physiologically acceptable derivatives of said prodrugs of formulae (I) and (II) include salts, esters and salts of esters. Esters include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain C₁₋₆alkyl. (methyl,

n-propyl, n-butyl or t-butyl); or C₃₋₆cyclic alkyl (e.g. cyclohexyl). Salts include physiologically acceptable base salts, eg derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NR_n (wherein R is C₁₋₄ alkyl) salts. Other salts include acid addition salts, including the hydrochloride and acetate salts.

5 Preferred values of X and Y are independently chloro, iodo and mesyl.

Preferably, n either is zero or is 1 or 2 and the group(s) R¹ are independently fluorine, chlorine, bromine, iodine or C₁₋₄ alkyl. Similarly, it is preferred that either m is zero or is 1 or 2 and the group(s) R² are independently fluorine, chlorine, bromine, iodine or C₁₋₄ alkyl.

10 R³ is preferably hydrogen.

Z³ is preferably a group -V-W where V is -CH₂CH₂- and W is a group -COOH, -(C=O)-OR⁶ where R⁶ is as defined above, or -(C=O)-NR⁷R⁸ where R⁷ and R⁸ are independently hydrogen or C₁₋₆ alkyl.

Preferred compounds of the formula (I) are those in which Z¹, Z², n and m are as defined 15 above, and:

X and Y are independently selected from chloro, iodo or mesyl; each phenylene group which may be optionally substituted by R¹ and R² is unsubstituted or if either is substituted, the group(s) R¹ and/or R² are independently selected from fluorine, chlorine, bromine, iodine or C₁₋₄ alkyl;

20 R³ is hydrogen; and

Z³ is a group -CH₂CH₂-COOH.

Compounds of the formula (I) which are especially preferred are those in which X and Y 25 independently represent iodo or chloro; n and m are both zero; R₁ represents hydrogen; Z₁ and Z₂ each independently represent -NH- or -O-; and Z₃ represents CH₂CH₂COOH.

Preferred compounds of the formula (II) are those in which Z¹ is -O- or -NH-, X and Y are independently selected from iodo and mesyl, each phenylene group which may be optionally substituted by R¹ and R² is unsubstituted or if either is substituted, the group(s) R¹ and/or R² are independently selected from fluorine, chlorine, bromine, iodine or C₁₋₄ alkyl, 5 most preferably fluorine, and in which case n and/or m are 1 or 2.

Compounds of the formula (II) which are especially preferred are those in which X represents iodo; n represents zero; Z¹ represents -O- or -NH-; R₂ represents hydrogen or fluorine; and m represents an integer from 1 or 2.

The invention further provides pharmaceutical formulations. Such formulations comprise a 10 compound of formula (I) or (II) together with one or more pharmaceutically acceptable carriers or diluents.

Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral or parenteral (e.g. intramuscular or intravenous) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the 15 methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

For example, formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatics and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to 25 target the polypeptide to blood components or one or more organs.

Suitable liposomes include, for example, those comprising the positively charged lipid (N[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA), those comprising dioleoyl-

phosphatidylethanolamine (DOPE), and those comprising 3β [N-(n',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol).

In GDEPT the prodrug will usually be administered following the administration of a delivery system containing the gene encoding the enzyme. This includes administration of a modified 5 virus encoding an enzyme. Typically, the virus will be administered to the patient and then the uptake of the virus by infected cells monitored, for example by recovery and analysis of a biopsy sample of targeted tissue.

A wide range of viral delivery systems for gene therapy are known in the art. For example EP-A-415 731 describes molecular chimeras comprising a promoter which may be activated 10 in a tumour cell is operably linked to a heterologous gene encoding an enzyme capable of converting a prodrug into a cytotoxic agent. Such molecular chimeras may be used to express carboxypeptidase or nitroreductase in tumour cells, in order to activate prodrugs of the invention. EP-A-415 731 describes incorporation of such molecular chimeras into viral vectors, e.g. adenoviral or retroviral vectors. Such viral vectors may also be adapted for 15 utilization in the present invention.

Other recombinant viral vector delivery systems are described in WO91/02805, WO92/14829, WO93/10814, WO94/21792, WO95/07994 and WO95/14091 the disclosures of which are incorporated herein by reference. Methods for producing vector delivery systems based on the above-mentioned disclosures may be used to deliver vectors encoding nitroreductase or 20 carboxypeptidase to target cells.

The exact dosage regime for GDEPT will, of course, need to be determined by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of the prodrug and the cytotoxic agent to be released from the prodrug but some general guidance can be given. Chemotherapy of this type will normally involve parenteral 25 administration of both the prodrug and the enzyme or a vector encoding the enzyme and administration by the intravenous route is frequently found to be the most practical.

In GDEPT systems, the amount of vector delivered will be such as to provide an effective cellular concentration of enzyme so that the prodrug may be activated in sufficient

concentrations at the site of a tumour to achieve a therapeutic effect, e.g. reduction in the tumour size. This may be determined by clinical trials which involve administering a range of trial doses to a patient and measuring the degree of infection or transfection of a target cell or tumour. The amount of prodrug required will be similar to or greater than that for ADEPT systems of the type mentioned above. For example, suitable dose of prodrugs in such systems are described in Bagshawe *et al*, 1991 in Antibody, Immunoconjugates and Radio-Pharmaceuticals I. 915-922. Such doses eg. from 5 to 2000 mg/m² (eg about 200 mg/m² per dose (eg every one or two days or weekly) of prodrugs of the invention may be used, although doses outside this range may be used at the discretion of the physician.

5 10 The present invention also provides a system for use in the control of neoplasia in a human or animal subject comprising a vector or other delivery system capable of selectively infecting tumour cells in said subject, said vector carrying a DNA or RNA sequence encoding an enzyme, in association with a prodrug of formula (I) or (II) capable of being converted to a nitrogen mustard compound by the action of said enzyme.

15 20 The present invention extends to a method of treating neoplasia in a human or animal subject requiring such treatment which comprises administering to the host an effective amount of a prodrug of the invention and a modified virus, said modified virus capable of selectively infecting tumour cells in said subject, said virus carrying a DNA or RNA sequence encoding an enzyme capable of converting said prodrug to an active nitrogen mustard compound.

25 20 The present invention also extends to a method of treating neoplasia in a human or animal subject requiring such treatment which comprises administering to the host an effective amount of a prodrug of the invention and a non viral vector system, said non-viral vector system capable of being selectively introduced into tumour cells in said subject, said vector system carrying a DNA or RNA sequence encoding an enzyme capable of converting said prodrug to an active nitrogen mustard operably linked to a promoter effective in expressing said enzyme in said cells.

Vectors capable of selectively infecting tumour cells are known in the art. By "selectively infecting" it is meant that the vector, for example a modified virus, will primarily infect cancer cells and that the proportion of non-tumour cells infected is such that the damage to

non-tumour cells by administration of the prodrug will be acceptably low, given the nature of the disease being treated. Ultimately, this will be determined by the physician.


It will also be understood that the DNA or RNA sequence encoding an enzyme carried by the virus will be linked to suitable expression control signals such that expression of the enzyme 5 will occur in the targeted tumour cells.

Non-viral vector systems will be capable of being selectively introduced into tumour cells utilizing methods such as those mentioned above, e.g. calcium phosphate co-precipitation, microinjection, liposomes, direct DNA uptake, and receptor-mediated DNA transfer (Morgan & French Anderson, *Annu. Rev. Biochem.*, 1993, 62; 191).


10 Prodrugs of the present invention may also be used as reagents in *in vitro* systems to test the activity of candidate enzymes which may be incorporated into GDEPT systems.

For example, a tumour cell may be infected or transfected *in vitro* by a vector containing an enzyme. The enzyme will be one which is, or suspected to be, capable of converting a prodrug of the invention into an active drug. The prodrug is then added to the culture and 15 the amount of cell killing or inhibition of cell growth is measured (for example by using a vital stain to record the number of viable cells or by replating a sample of the culture to count the number of viable cells). This model system may also be used to test the toxicity, activity or selectivity of compounds of the present invention against a range of tumour cell types suitable tumour cells for use in these model systems include ovarian, colon, glioma, breast, small cell and non-small cell lung cancer cells, and melanomas.

The invention further provides processes for the production of compounds of formulae (I) and (II). Thus the invention provides a process for the production of a compound of formula (I) as defined above which comprises reacting a compound of the formula (III)




in which X, Y, R¹ and n are as defined for formula (I) and Z⁴ is -O- or -NH- with a compound of formula (IV)



in which R², m, Z², Z³ and R³ are as defined above, and Q is a leaving group. The reaction may be performed in an aprotic solvent and in the presence of a base. The invention also provides a process for the production of compounds of the formula (II) which comprises reacting a compound of formula (III) as defined above with a 4-nitrobenzyl chloroformate optionally substituted with from 1 to 4 group(s) R² as defined above.

The invention further provides compounds of the formula (IV):



in which R², m, Z², R³ and Z³ are as defined above for compounds of the formula (I), and Q is a leaving group, with the proviso that when R² is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and C₁₋₄ haloalkenyl, R³ is hydrogen or a C₁₋₆alkyl group, and Z³ is a group -CH₂CH₂COOX¹⁰ where X¹⁰ is hydrogen or a C1-6alkyl group, then Q is not a N-succinimidyl group. These compounds are useful as linkers which may be attached to active cytotoxic compounds to provide prodrugs of said compounds with increased lipophilicity. The compounds of formula (IV) may be linked to such cytotoxic compounds via free -OH or -NH₂ groups on such compounds, using methods and reactions described below, or modified using routine experimentation.

Such protected cytotoxic compounds may be useful in GDEPT methods, or *in vitro* assays used to study such methods.

Brief Description of the Drawings

Figure 1 provides a reaction scheme used to make the compounds described in Example 9.


15 Figure 2 provides a reaction scheme used to make the compounds described in Example 15.

Figure 3 provides a reaction scheme used to make the compounds of the invention described in Examples 1, 2, 3 and 4.


Compounds of the invention may be made using reactions and methods known per se in the art of chemistry. The following methods are of particular use, and are further illustrated by reference to the Examples where indicated. Such reference does not limit the general reaction schemes to those compounds alone. The schemes may be used for other compounds of the invention:

A: Compounds of formula (I) where Z¹ is -O-:

(i) Compounds of formula (I) in which $Z^1 = -O-$ and $Z^2 = -NH-$, may be prepared by the reaction of a nitrogen mustard of formula (III)



wherein X, Y, R^1 and n are as defined above and Z^4 is -O- with a linker of formula (IV)




where R^2 , m, R^3 and Z^3 are as defined above, $Z^2 = -NH-$ and Q is a leaving group.

5 Preferred leaving groups Q include a succinimidyl group, a 4-nitrophenyloxy group, a pentafluorophenyloxy group and a tetrachloroethoxy $CH(Cl)CCl_3$ group. The reaction may be carried out in aprotic solvents in the presence of a base, for example THF and triethylamine or acetonitrile and basic resins (Example 1).

(ii) Compounds of the formula (III) may be made starting from 4-nitrophenol optionally substituted with the group(s) $R^1(n)$, (as defined above). The phenolic group is

protected as an adamantanyloxycarbonyl-derivative (by reacting the starting materials with adamantanyl-fluoroformate and triethylamine in THF at rt). The protected 4-nitrophenyl carbonate is reduced to the corresponding amine by hydrogen transfer in ethanol using ammonium formate and Pd/C 10% as catalyst at rt. The amine is then hydroxyethylated with ethylene oxide in AcOH at 20°C and then reacted to the desired nitrogen mustard. Reference may be made to EP-A-433 360 or EP-A-490970 for suitable conditions. The compounds may be purified by column chromatography. Deprotection to remove the adamantyl group may be carried out in trifluoroacetic acid.

(iii) Alternatively, the nitrogen mustard of formula (III) may be activated as a chloroformate by treatment with phosgene or triphosgene in an aprotic solvent and triethylamine followed by coupling with a compound of formula (V):



where R², m, Z², R³ and Z³ are as defined above. This may be carried out in THF or other aprotic solvents in the present of a base (for example triethylamine or pyridine).

(iv) A further alternative route of synthesis of compounds of the formula (I) in which Z¹ is -O- involves direct coupling of 4-nitrophenol optionally substituted with the group(s) R¹⁽ⁿ⁾ (as defined above) with the compound of the formula (IV) or by reaction of the said optionally substituted 4-nitrophenol compound chloroformate with the compound of formula (VI), in which Z² is -NH- (see below) followed in each case by the reaction described above to convert the nitro group, via an amine, to a mustard group.

(v). A way of obtaining compound (I) where $Z^1 = -O-$ and $Z^2 = -O-$ is from nitrogen mustard (III) where $Z^4 = -O-$, by transforming it to the trimethylsilyl derivative. The silylated phenol is then coupled with a compound of formula (V) where $Z^2 = -O-$. Compound (V) is first activated as the fluoroformate with KF, phosgene and crown ether at -78°C , in an aprotic solvent (see Example 2), prior to reaction with silylated phenol.

B: Compounds of formula (I) where Z^1 is $-\text{NH}-$:

(i) Compounds of the formula (I) in which Z^1 is $-\text{NH}-$ may be made by reaction of a compound of formula (III) in which Z^4 is $-\text{NH}-$ with a linker of the formula (IV) in aprotic solvents and in the presence of a base. Compounds of the formula (III) in which Z^4 is $-\text{NH}-$ may be made from a 1-halo-4-nitrophenyl compound, optionally substituted with the group(s) $R^1_{(n)}$ (as defined above). This is converted to the corresponding 1-bis-hydroxyethylamino-4-nitrophenyl compound by reaction with diethanolamine with heat and the resulting product purified by column chromatography. The corresponding 4-nitro nitrogen mustard may be made by for example mesylation using mesyl chloride in pyridine and subsequent reaction to other halo mustards, e.g. bromo or iodo mustards if required. The 4-nitro group may be reduced by hydrogen transfer in ethanol using ammonium formate and a Pd/C 10% catalyst at 20°C .

(ii) Alternatively the 1-bis-hydroxyethylamino-4-nitrophenyl compound mentioned above can be reduced using ammonium formate and Pd/C 10% as catalyst in ethanol at 20°C to provide the corresponding phenylene-diamino derivative. This derivative can be converted into the corresponding 4-amino nitrogen mustard as described in the above paragraph, e.g. initially by reaction with mesyl chloride.

(iii) In an alternative route, the nitrogen mustard (III) $Z^4 = -\text{NH}-$ may be activated as an isocyanate by treatment with phosgene or triphosgene in an aprotic solvent followed by coupling with a compound of formula V where R^2 , m, Z^2 , R^3 and Z^3 are as defined above. The coupling may be carried out in aprotic solvents and in the presence of a catalyst, for example dibutyltin dilaurate (see Examples 3 and 4).


C: Compounds of formula (II):

(i) Compounds of the formula (II) may be obtained by coupling nitrogen mustard phenol compounds described in section A(ii) above with 4-nitrobenzyl chloroformate optionally substituted with the group(s) $R^2_{(n)}$, (as defined above) in the presence or absence 5 of triethylamine at 20°C. This is used to provide compounds of formula (II) in which Z^1 is -O-

(ii) Alternatively aniline nitrogen mustards as described in section B(ii) above may be used with the chloroformate as described in section C(i) above. This is used to provide compounds of the formula (II) in which Z^1 is -NH-.

10 D: Compounds of the formula (IV) in which Z^2 is -NH-:

(i) Compounds of the formula (IV) in which Z^2 is -NH- may be made from a 4-nitro benzylic alcohol optionally substituted with the group(s) $R^2_{(m)}$, (as defined above). The hydroxyl function is protected as a pyanyl- or *t*-butyl-dimethylsilyl (TBDMSi)-ether by treatment at 20°C with 3,4-2H-dihydropyran and pyridinium-p-toluenesulfonate (PPTS) in an 15 aprotic solvent or with TBDMSi chloride and imidazole in dimethylformamide (DMAT), respectively (Example 5). The intermediate thus obtained is reduced to the corresponding amine by hydrogen transfer in ethanol using ammonium formate and Pd/C 10% as catalyst at 20°C. This amine is converted to a glutamyl ester intermediate of formula (VI) (Example 6):



where R², m, R³ and Z³ are as defined above, Z² is -NH- and Pr is the pyanyl- or *t*-butyl-dimethylsilyl (TBDMSi)-ether protecting group. This may be done by treating the amine with triphosgene and triethylamine in toluene at 60°C to provide the corresponding isocyanate, which is coupled with a glutamate derivative of formula R³O-C(O)-CH(NH₂)-Z³ where R³ and Z are as defined above. Alternatively the corresponding glutamyl-isocyanate obtained from the corresponding glutamate by treatment with triphosgene and triethylamine in toluene at -78°C may be reacted with the amine in a one pot procedure (Example 7). Glutamate derivatives of formula R³O-C(O)-CH(NH₂)-Z³ may be obtained by reference to WO94/02450. Where necessary or desired, the group Z³ may be converted to another group 10 Z³ using routine chemistry known *per se* following production of the compound of formula (VI), or after reaction of that to the compound of formula (I).

(ii) The compound of formula (VI) is deprotected to remove the TBDMSi or pyranyl groups by treatment with mild acidic media (AcOH, THF and H₂O or PPTS, EtOH, 55°C) (Example 8). This yields a compound of formula (VI) in which Pr is hydrogen. Compounds 15 of the formula (IV) in which Q is a leaving group may be prepared using standard reactions known in the art (Example 8).

(iii) Where Q is a succinimidyl group the compound of formula (VI) where Pr is hydrogen may be treated with disuccinimidyl-carbonate and triethylamine in acetonitrile. Where a 4-nitrophenyl carbonate group is desired treatment with 4-nitrophenyl chloroformate 20 and triethylamine in THF may be used (Example 9). A pentafluorophenyl carbonate may be added by *in situ* phosgenation of pentafluorophenol followed by coupling to the linker of formula (VI) in which Pr is hydrogen.

(iv) The compound of formula (VI) in which Pr is hydrogen may be obtained directly by coupling of the 4-aminobenzylic alcohol with glutamyl-isocyanate in aprotic solvents 25 (Example 10).

E: Compounds of the formula (IV) in which Z² is -O-:

(i) The starting materials for the linkers possessing a carbamic bond are unsubstituted or substituted (with the group(s) R², m, (as defined above)) 4-hydroxy-benzylic

alcohols. These type of linkers may require an extra electron withdrawing group on the aromatic nucleus in order to undergo 1,4-elimination. The 4-hydroxy group is specifically protected as an acetate by treating the starting material with acetyl-v-triazolo-[4,5-b]pyridine, and 1N NaOH in THF at 20°C. The alcohol function of the acetate is further protected as 10 pyranyl- or TBDMSi-ether by the procedures described in section D above. The acetate function is then deprotected to restore the 4-hydroxy group in NaHCO₃, aq. MeOH at 20°C. The resulting phenol compounds are reacted in a one pot procedure with a protected glutamyl-isocyanate as described in section D(i) above. This yields a compound of the formula of (VI) as shown above in which Z² is -O- and Pr is the pyranyl- or t-butyl-dimethylsilyl (TBDMSi)-ether protecting group.

(ii) Deprotection of this compound yields a compound of the formula (VI) in which Pr is hydrogen. This may be converted to compounds of the formula (IV) by methods analogous to those described in section D (iii) above.

(iii) An alternative procedure starts from 4-hydroxy-benzaldehyde which is protected with 1,3-propane-dithiol in the presence of BF₃.Et₂O, at room temperature, to give the 4[2'-(1',3'-S,S-dithianyl)]phenol. The coupling of the protected phenol with glutamyl isocyanate in toluene in the presence of Et₃N provides the di-*tert*-butyl.O-{4-[2'(1',3'-S,S-dithianyl)]phenyl}oxycarbonyl-L-glutamate. The deprotection of this intermediate to the corresponding aldehyde, is carried out with Hg(ClO₄)₂ in THF at room temperature. The reduction of the aldehyde with a reducing agent like sodium cyano-borohydride yields the desired compound of formula (VI) in which Pr is hydrogen and Z² is -O- (Example 11).

(iv) Another procedure to obtain the deprotected aldehyde is by direct coupling of 4-hydroxy-benzaldehyde with the glutamyl-isocyanate (Example 12).

(v) An alternative route to the compound of formula (VI) in which Z² is -O- and Pr is hydrogen is by direct coupling of the 4-hydroxy-benzylic alcohol, as potassium phenolate obtained from the starting material and potassium *tert*-butoxyde in the presence of crown ether) with the corresponding glutamyl-isocyanate in aprotic solvents (Example 13).

(vi) The compound of formula (IV) in which Z² is -O- and Q is a leaving group may be prepared using standard reactions known in the art. For example where Q is a 4-nitrophenyl carbonate group the compound of formula (VI) where Pr is hydrogen may be treated with 4-nitrophenyl chloroformate and triethylamine in THF (Example 14).

5 F: Alternative synthesis of compounds of formula (IV):

Compounds of the formula (IV) in which Q is hydrogen, fluoro, chloro, bromo or -O-(N-succinimide) may also be obtained by reference to WO95/03830 published on 9 February 1995 or WO95/02420 published 26 January 1995, the contents of which are hereby incorporated by reference.

10 The following Examples illustrate the invention. The numbering of compounds given in the examples is according to that shown in schemes 1-3.

Example 1.

Diallyl,[(4'-(N,N-bis(2-chloroethyl)amino)phenoxy carbonyl-oxy-benzyl-4-carbamoyl-L-glutamate] (22)

15 Activated linker 15b (0.20 g, 0.37 mmol) and 4-N,N-bis(2-chloroethyl)aminophenol 21 (0.14 g, 0.60 mmol) was dissolved in 10 mL acetonitrile. Then 0.13 g of a strongly basic resin-Amberlyst 27 (OH form) was added and the reaction mixture stirred with the resin for 20 h. The resin was filtered off, and an additional 0.08 g of fresh resin was added. After 30 min of stirring, the second portion of resin was filtered off, and the solvent evaporated. The product was purified by column chromatography (eluent: cyclohexane:AcOEt 2:1), to afford 22 (82 mg, 32%). ¹H-NMR δ_H: 1.80-2.15 (2m, 2H, CH₂CH(NH)-), 2.30-2.45 (m, 2H, CH₂CO₂-allyl), 3.72 (s, 8H, N(CH₂CH₂Cl)₂), 4.30-4.40(m, 1H, CH-G), 4.55 (d, 2H, J=5.41, CH₂O allyl), 4.61 (d, 2H, J=5.31, CH₂O allyl), 5.13 (s, 2H, PhCH₂), 5.10-5.40 (m, 4H, CH₂= allyl), 5.80-6.00 (m, 2H, CH= allyl), 6.64 (d, 1H, J=8.13 Hz, NH-G), 6.75 (d, 2H, J=9.10 H_{arom2+6}), 7.04 (d, 2H, H_{arom3+5}), 7.31 (d, 2H, J=8.55Hz, H_{arom2+6}), 7.41 (d, 2H, H_{arom3+5}), 8.69 (s, 1H, PhNH). MS (FAB). m/z: 636 (M+1, 60), 658 (M+23, 7). anal (C₃₀H₃₅N₃O₈Cl₂): calcd C 56.61, H 5.54, N 6.60; found C 56.49, H 5.69, N 6.27.

4'-(N,N-bis(2-chloroethyl)aminophenoxy carbonyl-oxy-benzyl-4-carbamoyl-L-glutamic acid (23)

To a solution of **22** (100 mg, 0.16 mmol), PPh₃ (92 mg, 0.35 mmol) and Pd(PPh₃)₄ (16 mg, 0.014 mmol) in CH₂Cl₂ (8 mL), acetic acid (1 mL) were added and the mixture stirred for 5 h under argon. The solvent was evaporated, and the residue kept under pump vacuum for 2 h, then dissolved in acetone:AcOEt 1:1. The acetone was evaporated affording **23**. PPh₃ was a precipitate in AcOEt. The solid was filtered, washed with AcOEt and then dissolved in 50 mL CHCl₃, and washed with aqueous citric acid 10% (2x50 mL). The organic layer was collected, H₂O was added and the CHCl₃ evaporated yielding **23** (28 mg, 32%) as a precipitate which was filtered from the aqueous solution. ¹H-NMR δ_H: 1.80-2.00 (2m, 2H, CH₂CH(NH)-), 2.15-2.25 (t, 2H, CH₂CO₂H), 3.72 (s, 8H, N(CH₂CH₂Cl)₂), 4.10-4.25(m.PhCH₂), 6.49 (d, 1H, J=7.34 Hz, NH-G), 6.75 (d, 2H, J=9.10 Hz, H_{arom2+6}), 7.05 (d, 2H, H_{arom3+s}), 7.29 (d, 2H, J=8.53 Hz, H_{arom2+6}), 7.41 (d, 2H, H_{arom3+s}), 8.75 (s, 1H, PhNH). MS (FAB), m/z: 556 (M+1, 55), 578 (M+23, 100). Accurate mass (C₂₄H₂₇N₃O₈Cl₂Na): calcd. 578.1073; found 578.1070.

Example 2.

4'-(N,N-bis(2-chloroethyl)aminophenol-trimethylsilyl ether (25)

Phenol nitrogen mustard **21** (60 mg, 0.26 mmol) and Me₃SiCN (40 μL, 0.3 mmol) were stirred at room temperature without solvent for 30 min; then 10 mL boiling hexane was added to the reaction mixture and the remaining solid filtered off. After evaporation of the hexane, **25** (70 mg, 88%) resulted as an oil. ¹H-NMR δ_H: 0.20 (s, 9H, Si(CH₃)₃), 3.55-3.70 (m, 8H, N(CH₂CH₂Cl)₂), 6.65 (d, 2H, J=9.30 Hz, H_{arom2+6}), 6.73 (d, 2H, H_{arom3+s}) MS (FAB), m/z: 304 (M+, 100). Accurate mass. (C₁₃H₂₁Cl₂NOSi) calcd. 305.0769; found 305.0765.

diallyl,[(4'-(N,N-bis(2-chloroethyl)amino)phenoxy carbonyl-oxy-benzyl-4-oxycarbonyl-L-glutamate] (26)

To a stirred solution of **14b** (100 mg, 0.26 mmol) in CH₂Cl₂ (5 mL) at -78°C, was added phosgene (20% solution in toluene, 150 μL, 0.3 mmol), KF (200 mg, 3.45 mmol) and 18-crown-6 ether (25 μL 0.12 mmol). After 1 h at -78°C, fluoroformate **24** was formed as indicated by IR spectra (ν_{OCOF}=1827 cm⁻¹). Silylated phenol **25** (70 mg, 0.23 mmol) in CH₂Cl₂ (3 mL) was added and the solution stirred 1 h more at -78°C, then filtered and the filtrate evaporated. After purification by preparative HPLC (eluent: cyclohexane:AcOEt 4:1).

26 (60 mg, 41%) resulted. $^1\text{H-NMR}$ δ_{H} : 1.90-2.20 (2m, 2H, $\text{CH}_2\text{CH}(\text{NH})-$), 2.45-2.60 (m, 2H, $\text{CH}_2\text{CO}_2\text{-allyl}$), 3.72 (s, 8H, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$), 4.15-4.25(m, 1H, CH-G), 4.57 (d 2H, $J=5.40$, CH_2O allyl), 4.63 (d, 2H, $J=5.28$ Hz, CH_2O allyl), 5.23 (s, 2H, PhCH_2), 5.15-5.35 (m, 4H, $\text{CH}_2=$ allyl), 5.85-6.00 (m, 2H, $\text{CH}=$ allyl), 6.75 (d, 2H, $J=9.11$ Hz, H), 7.06 (d, 2H, $\text{H}_{\text{arom}3+5}$), 7.14 (d, 2H, $J=8.51$ Hz, $\text{H}_{\text{arom}3+5}$), 7.41 (d, 2H, $\text{H}_{\text{arom}2+6}$), 8.31 (d, 1H, $J=7.77$, NH-G); MS (FAB) m/z: 637 (M, 100)

4'-(N,N-bis(2-chloroethyl)amino)phenyl-oxy-carbonyl-oxy-benzyl-4-oxycarbonyl-L-glutamic acid (27)

To a solution of 26 (40 mg, 0.063 mmol), PPh₃ (63 mg, 0.24 mmol) and Pd(PPh₃)₄ (12 mg, 0.01 mmol) in CH_2Cl_2 (3 mL), acetic acid (80 μL) was added and the mixture stirred for 2 h under argon. The solvent was evaporated and the residue dissolved in AcOEt (25 mL), washed with aqueous citric acid 5% (25 mL) and with H_2O (25 mL). The organic layer was dried over MgSO₄ and the solvent evaporated. After purification by preparative HPLC (eluent $\text{CH}_2\text{Cl}_2\text{:EtOH:AcOH}$ 90:5:5) 27 (8 mg, 25%) resulted. $^1\text{H-NMR}$ (CD_3COOD), 5H, 1.90-2.20 ($\text{CH}_2\text{CH}(\text{NH})-$), 2.61 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$), 3.60-3.75 (m, 8H, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$), 4.45-4.55 (m, 1H, CH-G), 5.23 (s, 2H PhCH_2), 6.73 (d, 2H, $J=9.20$ Hz, $\text{H}_{\text{arom}2+6}$), 7.06 (d, 2H, $\text{H}_{\text{arom}3+5}$), 7.19 (d, 2H, $J=8.59$ Hz, $\text{H}_{\text{arom}3+5}$), 7.45 (δ , 2H, $\text{H}_{\text{arom}2+6}$); MS, (ESI) m/z: 557 (M+1, 3).

Example 3.

di-t-butyl,[(4'-(N,N-bis(2-chloroethyl)amino)phenylcarbamoyl-oxy-benzyl-4-oxycarbonyl-L-glutamate (17)

To a solution of 14a (60 mg 0.15 mmol) in toluene (5 mL) was added isocyanate 16 (0.60 mmol) in toluene (5 mL) and dibutyltin dilaurate (10 μL). The reaction mixture was stirred for 12 h at room temperature. The solid which formed was filtered off and the filtrate evaporated. Purification was achieved by column chromatography (eluent: cyclohexane:AcOEt 3:1), when product 17 (90 mg, 90%) was obtained as an oil. $^1\text{H-NMR}$ δ_{H} : 1.41 (s, 9H, *t*-Bu), 1.42 (s, 9H, *t*-Bu), 1.65-2.05 (2m, 2H, $\text{CH}_2\text{CH}(\text{NH})-$), 2.30-2.40 (m, 2H, $\text{CH}_2\text{CO}_2\text{-t-Bu}$), 3.68 (s, 8H, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$), 3.95-4.15 (m, 1H, CH-G), 5.10 (s, 2H, PhCH_2), 6.70 (d, 2H, $J=8.75$ Hz, $\text{H}_{\text{arom}3+5}$), 7.10 (d, 2H, $J=8.31$ Hz, $\text{H}_{\text{arom}3+5}$), 7.28 (d, 2H, $\text{H}_{\text{arom}2+6}$), 7.42 (d, 2H, $\text{H}_{\text{arom}2+6}$), 8.92 (d, 1H, $J=7.80$ Hz, NH-G), 9.36 (s, 1H, Ph'-NH). MS, m/z (FAB): 667 (M+1, 5), 689 (M+23, 100)

4'-[N,N-bis(2-chloroethyl)aminophenylcarbamoyl-oxy-benzyl-4-carbamoyl-L-glutamic acid (18)

Di-*t*-butyl ester **17** (90 mg, 0.135 mmol) was dissolved in formic acid (10 mL) and stirred under argon at 12 °C for 24 h. The reaction mixture was lyophilised, the freeze-dried material triturated with CH₂Cl₂, the solvent removed and the solid kept in a dessicator 24 h under vacuum to afford **18** (65 mg, 87%). ¹H-NMR δ_H: 1.75-2.15 (2m, 2H, CH₂CH(NH)-), 2.30-2.50 (m, 2H, CH₂CO₂H), 3.68 (s, 8H, N(CH₂CH₂Cl)₂), 3.95-4.10 (m, 1H, CH-G), 5.10 (s, 2H, PhCH₂), 6.70 (d, 2H, J=8.66Hz, H_{arom3+5}), 7.11 (d, 2H, J=8.29, H_{arom3+5}), 7.28 (d, 2H, H_{arom2+6}), 7.42 (d, 2H, H_{arom2+6}), 8.07 (d, 1H, J=7.80 Hz, NH-G), 9.36 (s, 1H, Ph'NH). MS, m/z (FAB): 555 (M, 90), 578 (M+23, 100). Accurate mass: calcd: (C₂₄H₂₇N₃O₈Cl₂Na), 578.1073, found: 578.1070.

Example 4.

diallyl-[4'-(N,N-bis(2-chloroethyl)amino)phenylcarbamoyl-oxy-benzyl-4-carbamoyl-L-glutamate] (19)

15 A similar procedure as for **17** was used, starting from isocyanate **16** (0.54 mmol) in toluene (5 mL), **8b** (0.10 g, 0.27 mmol) dissolved in CH₂Cl₂ (5 mL), and dibutyltin dilaurate (10 μL), to yield **19** as a solid. After further recrystallisation from hexane:AcOEt 9:2 **19** (0.11 mg, 64%) resulted. ¹H-NMR δ_H: 1.75-2.15 (2m, 2H, CH₂CH(NH)-), 2.35-2.50 (m, 2H, CH₂CO₂-Allyl), 3.68 (s, 8H, N(CH₂CH₂Cl)₂), 4.25-4.40(m, 1H, CH-G), 4.55 (d, 2H, J=5.39 Hz, CH₂O allyl), 4.61 (d, 2H, J=5.37 Hz, CH₂O allyl), 5.01 (s, 2H, PhCH₂), 5.15-5.35 (m, 4H, CH₂= allyl), 5.80-6.05 (m, 2H, CH= allyl), 6.61 (d, 1H, J=7.97 Hz, NH-G), 6.69 (d, 2H, J=8.99Hz, H_{arom3+5}), 7.28 (d, 4H, J=7.79 Hz, H_{arom2+6}+H_{arom2+6}), 7.39 (d, 1H, H_{arom3+5}), 8.64 (s, 1H, PhNH), 9.30 (s, 1H, Ph'NH). MS, m/z (FAB): 635 (M+1, 5), 657 (M+23, 5).

25 4'-[N,N-bis(2-chloroethyl)aminophenylcarbamoyl-oxy-benzyl-4-carbamoyl-L-glutamic acid (20)

Diallyl ester **19** (40 mg, 0.06 mmol) dissolved in CH₂Cl₂ (2 mL) was stirred with Pd(PPh₃)₄ (4 mg) and pyrrolidine (15 μL, 0.15 mmol) The reaction mixture was kept under argon for 45 min then diluted with 2 mL toluene. The pyrrolidine salt of the acid **20** precipitated and was recovered by filtration. The free acid was obtained by extracting the precipitate with CH₂Cl₂/aqueous citric acid 10%. The organic layer was washed with H₂O and evaporated to

give the free acid (20 mg, 60%) after filtration of the remaining water. $^1\text{H-NMR}$ δ_{H} : 1.70-2.05 (2m, 2H, $\text{CH}_2\text{CH}(\text{NH})-$), 2.20-2.35 (m, 2H, CH_2CO_2 -allyl), 3.68 (s, 8H, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$), 4.15-4.30(m, 1H, CH-G), 5.01 (s, 2H, PhCH_2), 6.45 (d, 1H, $J=7.98\text{Hz}$, NH-G), 6.69 (d, 2H, $J=9.05\text{Hz}$, $\text{H}_{\text{arom}3+5}$), 7.27 (d, 4H, $J=8.60\text{Hz}$, $\text{H}_{\text{arom}2+6} + \text{H}_{\text{arom}2'+6'}$), 7.39 (d, 2H, $J=8.52\text{Hz}$, $\text{H}_{\text{arom}3+5'}$), 8.65 (s, 1H, PhNH), 9.30 (s, 1H, Ph'NH). MS (FAB). m/z: 554 (M. 50), 577 (M+23, 100). Accurate mass: calcd: ($\text{C}_{24}\text{H}_{28}\text{N}_4\text{O}_2\text{Cl}_2\text{Na}$) 577.1233, found: 577.1230.

Example 5.

(4-nitro-benzyl) *t*-butyl-di-phenyl-silyl ether (2a).

To a stirred solution of 4-nitrobenzyl alcohol (1.00 g, 6.50 mmol) and imidazole (0.97 g, 14.10 mmol) in DMF (10.0 mL), *t*-butyl-diphenyl-chlorosilane (1.98 g, 1.87 mL, 7.20 mmol) was added over 10 min under nitrogen at room temperature. The reaction mixture was stirred for an additional 5 h, diluted with 75 mL Et_2O , washed with H_2O (5 times, 15 mL), dried (MgSO_4) and evaporated under vacuum. An oil which crystallised on standing, resulted: yield: 2.54 g. After recrystallisation from EtOH 70%, 2.36 g (93%) of a white solid is obtained. mp 80-81 °C. $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 2931, 2857 (CH_2 , asym.. sym.). 1521, 1345 (NO_2): $^1\text{H-NMR}$, δ_{H} : 1.06(9H, s, *t*-Bu), 4.92 (2H, s, CH_2), 7.42-7.46 (5H, m, Ph), 7.63-7.65 (7H, m, Ph+ $\text{H}_{\text{arom}2+6}$), 8.23, (2H, d, $J = 8.23\text{ Hz}$, $\text{H}_{\text{arom}3+5}$); MS, (EI), (391.54); m/z: 334 (M - *t*-Bu, 100), 288 (M - *t*-Bu - NO_2 , 10), 256 (M - *t*-Bu - Ph, 20), 199 (Ph_2SiOH^+ , 100); $\text{C}_{23}\text{H}_{25}\text{NO}_2\text{Si}$.

20 4-nitro-benzyl -2'-tetrahydropyranyl ether(2b).

To a stirred solution of 4-nitrobenzyl alcohol (1.53 g, 10.0 mmol) in CH_2Cl_2 (50 mL), 3,4-dihydropyran (1.36 mL, 1.26 g, 15.0 mmol) and pyridinium-*p*-toluene sulphonate (0.25 g) were added. After 1.5 h the reaction mixture was evaporated to 4-5 mL, AcOEt (25 mL) was added and the solution washed with water (3x50mL), then brine, dried (MgSO_4) and evaporated under vacuum. The product, 2b, (2.46 g, 99%) resulted as an oil. $^1\text{H-NMR}$, δ_{H} : 1.51-1.63 (m, 4H, $2\text{H}_4+2\text{H}_5$), 1.66-1.74 (m, 1H, 2H_3), 3.50 (s, 1H, H_6), 3.78 (m, 1H, H_6), 4.62 (d, 1H, $J=3.8\text{ Hz}$, $\text{CH}_2\text{-Ph}$), 4.72 (m, 1H, H_2), 4.81 (d, 1H, $\text{CH}_2\text{-Ph}$), 7.62 (d, 2H, $J=8.5\text{ Hz}$, H_{arom}), 8.22 (d, 2H, H_{arom}); MS, (FAB), (237, 52); m/z: 260 (M⁺+23, 15), 236 (M - 1, 45), 136 (4- $\text{NO}_2\text{C}_6\text{H}_3\text{CH}_2^+$, 100).

Example 6.

(4-amino-benzyl) *t*-butyl-di-phenyl-silyl ether (3a)

To a stirred solution of **2a** (5.00 g, 12.80 mmol) in ethanol (100 mL) was added Pd/C 10% (1.50 g) and ammonium formate (4.60 g) in one portion at 20 °C. After 1.5 h the catalyst was removed by filtration, the filtrate concentrated under vacuum and the residue partitioned between EtOAc:H₂O. The organic layer was dried (MgSO₄) and concentrated to give **3a** as an oil; yield: 4.24 g (91 %); ν_{max} /cm⁻¹ (film): 3433, 3378 (NH₂), 2931, 2857 (CH₂, asym., sym.); ¹H-NMR, δ_{H} : 1.00 (s, 9H, *t*-Bu), 4.57 (s, 2H, CH₂), 4.98 (s broad, 2H, NH₂), 6.52 (d, 2H, J = 8.25 Hz, H_{arom3+5}), 6.96 (d, 2H, H_{arom2+6}), 7.42-7.46 (m, 5H, Ph), 7.62-7.65 (m, 5H, Ph); MS, (EI), (361.56); m/z: 361 (M⁺, 8), 304 (M - *t*-Bu, 100), 199 (Ph₂SiOH⁺, 100); anal (C₂₃H₂₇NOSi), C, H, N.

(4-amino-benzyl)-O-2'-tetrahydropyranyl ether (3b)

A similar method as for **3a** was employed using **2b** (8.53 g, 35.9 mmol) in ethanol (150 mL), Pd/C 10% (3.50 g) and ammonium formate (12.0 g, 180.0 mmol). An oil (6.40g, 36%) resulted after work up, which was purified by column chromatography (cyclohexane:AcOEt 1:1): The desired compound eluted first as an oil (2.59 g, 38%). ν_{max} /cm⁻¹ (film): 3447, 3360 (NH₂, sym, asym), 2943, 2870 (CH₂, asym., sym.); ¹H-NMR, δ_{H} : 1.42-1.53 (m, 4H, 2H, + 2H_c), 1.55-1.72 (m, 1H, 2H_c), 3.45 (s, 1H, H_c), 3.79 (m, 1H, H_c), 4.22 (d, 1H, J=11.1 Hz, CH₂-Ph), 4.37 (d, 1H, CH₂-Ph), 4.60 (d, 1H, H_c), 5.00 (s, 2H, NH₂), 6.52 (d, 2H, J=8.23 Hz, H_{arom}), 6.97 (d, 2H, H_{arom}); MS, (EI), (207, 27); m/z: 207 (M⁺, 100), 106 (H₂NC₂H₅CH₂⁺, 100); anal (C₁₂H₁₇NO₂), C, H, N.

Example 7.

di-*t*-butyl,(*t*-butyl-di-phenyl-silyl-O-benzyl)-4-carbamoyl-L-glutamate(7a)

Method A: A suspension was formed by adding 0.31 g (0.43 mL, 3.1 mmol) triethylamine to a solution of di-*t*-butyl-glutamate hydrochloride (0.46 g, 1.55 mmol) in 7 mL THF. The isocyanate, **4a**, (0.60 g, 1.55 mmol) dissolved in 3 mL THF (dry) was added to this at room temperature. After 2 h the precipitate was filtered and the solvent removed under vacuum, giving 0.87 g (87%) of an oil. The product was purified by column chromatography (AcOEt: cyclohexane 2:1) yielding 0.53 g (53%) of pure **7a**, as a white solid, mp = 89-90 °C. ν_{max} /cm⁻¹ (film): 3359 (NH), 2932, 2857 (CH₂, asym., sym.), 1729 (C=O, ester), 1670 (C=O, urea), 1154 (C-O, str.); ¹H-NMR, δ_{H} : 1.03 (s, 9H, *t*-Bu), 1.40 (s, 9H, *t*-Bu-glu), 1.43 (s, 9H, *t*-Bu-glu), 1.68-2.00 (2m, 2H, CH(NH)CH₂), 2.18-2.32 (m, 2H, CH₂CO₂-*t*-Bu), 4.08-4.12 (m,

1H. $\text{CH}(\text{NH})\text{CH}_2$). 4.68 (s, 2H, PhCH_2), 6.38 (d, 1H, $J = 8.12$ Hz, NH-glu), 7.19 (d, 2H, $J = 8.41$ Hz, $\text{H}_{\text{arom}3+5}$), 7.32-7.47 (m, 7H, $\text{Ph} + \text{H}_{\text{arom}2+6}$), 7.62-7.70 (m, 5H, Ph), 8.54 (s, 1H, NH-Ph); MS, (EI), (646.90); m/z: 590 ($M - t\text{-Bu} + 1, 2$), 534 ($M - 2t\text{-Bu} + 2, 5$), 478 ($M - 3t\text{-Bu} + 3, 100$), 199 ($\text{Ph}_2\text{SiOH}^+, 100$); anal ($\text{C}_{37}\text{H}_{50}\text{N}_2\text{O}_6\text{Si}$). C, H, N.

Method B: One pot synthesis of compound 7a : To a solution of di-*t*-butyl-glutamate hydrochloride (4.14 g, 14.0 mmol) and triphosgene (1.39 g, 4.67 mmol) in toluene, cooled at -78 °C. 3.90 mL (2.83 g, 28 mmol) triethylamine in 10 mL toluene were added dropwise over 30 min. The reaction was allowed to reach room temperature and was completed by 1 h. To this mixture, a solution containing (4-amino-benzyl)*t*-butyl-diphenyl-silyl ether 3a (5.00 g, 13.8 mmol) and triethylamine (1.95 mL, 14.0 mmol) was added over 5-10 min. The reaction was completed by 20 h. The reaction mixture was filtered, washed with H_2O (200 mL), HCl solution 1% (200 mL), Na_2CO_3 solution 1% (200 mL), H_2O (twice, 200 mL), dried (MgSO_4) and evaporated under vacuum, yielding a thick oil. Yield: 9.90 g. (TLC, AcOEt : cyclohexane 3:1). The product was used for deprotection without further purification.

15 **diallyl-(2'-tetrahydropyranyl-O-benzyl)-4-carbamoyl-L-glutamate (7b)**

A similar one pot procedure was used. starting from diallyl glutamate-*p*-toluene-sulphonate (1.08 g, 3.1 mmol), triphosgene (0.30 g, 1.03 mmol) and triethylamine (0.86 mL, 0.63 g, 6.2 mmol) in toluene (20 mL) at -78 °C to prepare the diallyl-L-glutamyl isocyanate 6b. To

the reaction mixture 3b (0.52 g, 2.5 mmol) and triethylamine (0.41 mL) in 5mL toluene was added. An oil resulted (1.17 g) which was separated by preparative HPLC using cyclohexane:AcOEt 1.5:1 as eluent. The desired compound separated as an oil (0.75 g, 65%).

ν_{max} /cm⁻¹ (film): 3362 (NH₂), 2944, 2871 (CH₂, asym., sym.); ¹H-NMR, δ_{H} : 1.47-1.50 (m, 4H, 2H₁ + 2H₅), 1.60-1.68 (m, 3H, 2H₃ + CH₂CH(NH)-), 1.88-2.05 (m, 1H, -CH₂CH(NH)-), 2.37-2.45 (m, 2H, CH₂CO₂A), 3.45 (s, 1H, H₆), 3.80 (m, 1H, H₆), 4.20-4.31 (m, 1H, -CH(NH)-), 4.35 (d, 1H, $J=11.55$ Hz, CH₂-Ph), 4.53-4.63 (m, 5H, CH₂-Ph + CH₂O allyl),

5.18-5.33 (m, 4H, CH₂= allyl), 5.80-6.00 (m, 2H, CH= allyl), 6.60 (d, 1H, $J=8.03$ Hz, NH-G), 7.20 (d, 2H, $J=8.47$ Hz, H_{arom}), 7.35 (d, 2H, H_{arom}), 8.47 (s, 1H, NH-Ph); MS.

(EI), (460, 53); anal ($\text{C}_{24}\text{H}_{32}\text{N}_2\text{O}_7$). C, H, N.

Example 8.

di-*t*-butyl,(4-hydroxybenzyl)carbamoyl-L-glutamate (8a)

Tetra-butylammonium fluoride solution in THF (1M) 20.0 mL (2.5 eq) was added to compound 7a (5.15 g, 8.0 mmol) in 100 mL THF at room temperature. The reaction was finished in 3 h (TLC AcOEt : cyclohexane 3:1). The reaction mixture was evaporated under vacuum. The oil thus obtained was dissolved in AcOEt (50mL), washed with water (3x100 mL), dried (MgSO_4) and evaporated again. An oil (5.08 g) was obtained. The deprotected compound, 8a, was purified by column chromatography (AcOEt : cyclohexane 3:1) yielding 1.88g (58.5%) of an oil which crystallised on standing. Recrystallisation from 60% aqueous MeOH afforded a white solid. Mp : 103-104 °C; $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3370 (broad, NH+OH), 2967 (CH₃), 2930, 2857 (CH₂, asym., sym.), 1716 (C=O, ester), 1678 (C=O, amide), 1153 (C-O, str.); ¹H-NMR. δ_{H} : 1.40 (s, 9H, *t*-Bu), 1.42 (s, 9H, *t*-Bu), 1.72-2.00 (2m, 2H, CH(NH)CH₂), 2.20-2.31 (m, 2H, CH₂CO₂-*t*-Bu), 4.10-4.18 (m, 1H, CH(NH)CH₂), 4.39 (d, 2H, J = 5.36 Hz, CH₂), 4.99 (t, 1H, CH₂OH), 6.38 (d, 1H, J = 8.11 Hz, NH-¹³C), 7.16 (d, 2H, J = 8.35 Hz, H_{arom3+5}), 7.31 (d, 2H, H_{arom2+6}), 8.50 (s, 1H, NH-Ph); MS, (EI), (408.49); m/z: 408 (M⁺, 10), 352 (M - *t*-Bu + 1, 4), 296 (M - 2*t*-Bu + 2, 14); anal (C₂₁H₃₂N₂O₆). C.H.N.

diallyl,(4-hydroxybenzyl)carbamoyl-L-glutamate (8b)

The intermediate 7b (0.61 g, 1.3 mmol) was hydrolysed at 45 °C in 24.5 mL of a mixture AcOH:THF:H₂O 4:2:1 for 3.5 h. (monitored by TLC, eluent, AcOEt:cyclohexane 1:1). The reaction mixture was diluted with 50 mL H₂O, extracted with ether (2x25 mL), then with AcOEt (2x30 mL). The pooled organic layers were washed with water (2x30 mL), dried (MgSO_4) and evaporated to dryness (with addition of toluene, 2x30mL). An oil resulted (0.52 g) which was purified by preparative HPLC (cyclohexane:AcOEt 1:2), yielding compound 8b (0.221 g, 45%). $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3354 (NH₂, OH broad), 1737 (C=O, ester), 1659 (C=O, amide); ¹H-NMR, δ_{H} : 1.85-1.93 (m, 1H, CH₂CH(NH)-), 2.00-2.05 (m, 1H, -CH₂CH(NH)-), 2.46 (t, 2H, J=5.42 Hz, CH₂CO₂A), 4.26-4.35 (m, 1H, -CH(NH)-), 4.40 (d, 2H, J=5.64 Hz, CH₂-Ph), 4.55 (d, 2H, J=5.32 Hz, CH₂O allyl), 4.61 (d, 2H, CH₂O allyl), 4.98 (t, 1H, OH), 5.17-5.37 (m, 4H, CH₂= allyl), 5.85-5.94 (m, 2H, CH= allyl), 6.56 (d, 1H, J=8.03 Hz, NH-G), 7.17 (d, 2H, J=8.48 Hz, H_{arom}), 7.32 (d, 2H, H_{arom}), 8.52 (s, 1H, NH-Ph); MS, (EI), (376, 41); m/z: 399 (M⁺ + 23, 35), 377 (M⁺ + 1, 100), 359 (M⁺ - H₂O, 34); anal (C₁₉H₂₄N₂O₆). C. H. N.

Example 9.

di-t-butyl,[4(4'nitrophenyloxycarbonyl)oxybenzyl]-carbamoyl-L-glutamate (9a)

To a stirred solution of **8a** (0.20 g, 0.49 mmol) in dry THF (10 mL) were added 0.11 g (0.5 mmol) 4-nitrophenyl chloroformate and triethylamine (0.1 mL, 0.6 mmol) at room temperature. The reaction was complete by 1 h. The precipitate formed was filtered and the solution concentrated under vacuum. AcOEt (10 mL) was added, the solution washed with brine (2x10 mL), dried and evaporated again, giving an oil (0.28 g). The product was purified by column chromatography (0.16 g, 57%) and repurified by preparative HPLC (0.14 g). $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3349 (NH₂), 2979, 2932 (CH₂, asym., sym.), 1767 (C=O, carbonate), 1716 (C=O, ester), 1652 (C=O, amide), 1527, 1349 (NO₂); ¹H-NMR, δ_{H} : 1.39 (9H, s, *t*-Bu), 1.42 (9H, s, *t*-Bu), 1.67-2.05 (2H, 2m, CH₂CH(NH)-), 2.20-2.38 (2H, 2m, CH₂CO₂-*t*-Bu), 4.08-4.21 (1H, m, CH(NH)-), 4.63 (2H, s, CH₂Ph), 6.46 (1H, d, J = 7.99 Hz, NH-glu), 7.33 (2H, d, J = 8.61 Hz, H_{arom3+5}), 7.42 (2H, d, H_{arom2+6}), 7.56 (2H, d, J = 9.17, H_{arom1+4}), 8.30 (2H, d, H_{arom2+6}), 8.68 (1H, s, NH-Ph); MS, (EI), (573, 60); anal (C₂₈H₃₅N₃O₁₀), C, H, N.

diallyl,[4(4'nitrophenyloxycarbonyl)oxybenzyl]-carbamoyl-L-glutamate (9b)

Starting from **8b** (0.19 g, 0.50 mmol), **9b** was obtained by a similar procedure and purified by preparative HPLC. Compound **9b** resulted as a white solid (0.132 g, 48.6%). ¹H-NMR, δ_{H} : 1.86-1.95 (m, 1H, CH₂CH(NH)-), 2.03-2.12 (m, 1H, -CH₂CH(NH)-), 2.46 (t, 2H, J = 7.40 Hz, CH₂CO₂A), 4.33-4.48 (m, 1H, -CH(NH)-), 4.55 (d, 2H, J = 5.33 Hz, CH₂O allyl), 4.61 (d, 2H, CH₂O allyl), 5.17-5.38 (m, 4H, CH₂=allyl), 5.22 (s, 2H, CH₂Ph), 5.87-5.96 (m, 2H, CH=allyl), 6.65 (d, 1H, J = 8.26 Hz, NH-G), 7.34 (d, 2H, J = 8.67 Hz, H_{arom}), 7.43 (d, 2H, H_{arom}), 7.56 (d, 2H, J = 9.14 Hz, H_{arom}), 8.31 (d, 2H, H_{arom}), 8.71 (s, 1H, NH-Ph); MS, (EI), (541,); m/z: 564 (M⁺ + 23, 60), 542 (M⁺ + 1, 6); anal (C₂₆H₂₇N₃O₁₀): C, H, N; accurate mass: calcd. (C₂₆H₂₇N₃O₁₀Na): 564.1594; found 564.1590.

Example 10.

diallyl,(4-hydroxybenzyl)carbamoyl-L-glutamate (8b)

To a solution of diallyl, glutamyl isocyanate **6b**, [prepared from diallyl glutamate-*p*-toluene sulphonate (10.0 g, 25.0 mmol), triphosgene (2.46 g, 8.3 mmol) and triethylamine (10.5 mL, 75.0 mmol, 3 eq) in 100 mL THF, at -78 °C] was added dropwise 4-aminobenzyl alcohol, **28**, (3.0 g, 24.3 mmol) and triethylamine (3.41 mL, 24.3 mmol) in 20 mL toluene, over 10

min at room temperature. The reaction was complete by 15 min. The reaction mixture was filtered, evaporated to dryness and the residue dissolved in 20 mL AcOEt, washed with water (2x20 mL), dried (MgSO_4) and re-evaporated. An oil resulted (10.25 g). 2.7 g of the obtained product was submitted to purification by preparative HPLC when 1.52 g (63%) of pure 8b resulted

Example 11.

di-*t*-butyl,{4[2'(1'3'-S,S-dithienyl)phenyloxycarbonyl-L-glutamate} (12).

To a solution of di-*t*-butyl-glutamyl isocyanate 6a (prepared from di-*t*-butyl-glutamate hydrochloride (1.50 g, 5.0 mmol), triphosgene (0.50 g, 1.66 mmol) and triethylamine (1.40 mL, 28.0 mmol) in 50 mL toluene, at -78 °C), was added 4[2'(1'3'-S,S-dithienyl)phenol], 11 (1.10g, 5.0 mmol) and triethylamine (0.70 mL). After 12 h, the solid formed was filtered and the solution washed with: NaOH 1% (75 mL), water (2x75 mL), dried (MgSO_4) and evaporated. A white solid (2.30 g, 95.8%) was obtained. Recrystallisation from aqueous EtOH 50% afforded the pure 12 (1.81 g, 72.7%). $\nu_{\max}/\text{cm}^{-1}$ (film): 3347 (NH₂), 2977, 2945 (CH₂, asym., sym.). 1728 (C=O, ester); ¹H-NMR, δ_{H} : 1.41 (s, 9H, *t*-Bu), 1.42 (s, 9H, *t*-Bu), 1.62-1.90 (m, 2H, CH₂-5'), 1.90-2.32 (2m, 2H, CH₂CH(NH)-), 2.30-2.40 (m, 2H, CH₂CO₂-*t*-Bu), 2.86-2.93 (m, 2H, CH₂-4' or 6'), 3.09 (t, 2H, J=12.3 Hz, CH₂-6' or 4'), 5.41 (s, 1H, H-2'). 7.08 (d, 2H, J = 8.50 Hz, H_{arom1-5}). 7.43 (d, 2H, H_{arom2+6}), 8.12 (d, 1H, J=7.81 Hz, NH-Ph); MS, (EI), (497, 67); m/z, : 497 (M⁺, 2), 451 (M - *t*-Bu , 2), 359 (M - 2*t*-Bu, 20); Anal.: (C₂₄H₂₅NO₆S₂), C, H, N.

di-*t*-butyl,(4-benzaldehyde)oxycarbonyl-L-glutamate (13a).

To the solution of dithiane 12 (0.50 g, 1.0 mmol) in CHCl₃ (10 mL) and THF (5 mL) was added dropwise a solution of Hg(ClO₄)₂.3H₂O (0.91 g, 2.0 mmol) in 5mL THF. After 5 min the precipitate was filtered and the solution is washed with H₂O (2x25 mL), sodium carbonate (25 mL), H₂O (2x25 mL), dried (MgSO_4) and evaporated. The compound 13a (0.33g, 81%) was obtained as a clear oil. $\nu_{\max}/\text{cm}^{-1}$ (film): 3347 (NH₂), 2979, 2934 (CH₂, asym.. sym.), 1731 (C=O, ester), 1712 (C=O, aldehyde); ¹H-NMR, δ_{H} : 1.41 (s, 9H, *t*-Bu), 1.43 (s, 9H, *t*-Bu), 1.80-1.87 (m, 1H, CH₂CH(NH)-), 1.96-2.02 (m, 1H, CH₂CH(NH)-), 2.32-2.39 (m, 2H, CH₂CO₂-*t*-Bu), 3.99-4.04 (m, 1H, CH-G), 7.34 (d, 2H, J = 8.39 Hz, H_{arom3+5}), 7.96 (d, 2H, H_{arom2+6}), 8.29 (d, 1H, J=7.72 Hz, NH-Ph), 9.98 (s, 1H, CHO):

di-t-butyl,(4-hydroxybenzyl)oxycarbonyl-L-glutamate (14a)

Compound 13a (0.150 g, 0.36 mmol) dissolved in 5.2 mL of a mixture of H₂O:AcOH:CH₃OH (1:1:1) was reduced with sodium-cyanoborohydride (0.027 g, 0.43 mmol) at room temperature. After 1 h, AcOEt (20 mL) was added, the reaction mixture 5 evaporated, the residue dissolved in AcOEt (20 mL), the solution washed with H₂O (20 mL), brine (2x20 mL), dried and evaporated to dryness. Compound 14a (0.127 g, 86%) was obtained as an oil. The final purification was achieved by preparative HPLC (cyclohexane:AcOEt, 2:1). $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3352 (NH₂, OH, broad), 2979, 2945 (CH₂, asym., sym.), 1728 (C=O, ester), 1712 (C=O, aldehyde); ¹H-NMR, δ_{H} : 1.41 (s, 9H, t-Bu), 10 1.42 (s, 9H, t-Bu), 1.70-1.82 (m, 1H, CH₂CH(NH)-), 1.94-1.99 (m, 1H, CH₂CH(NH)-), 2.31-2.38 (m, 2H, CH₂CO₂-t-Bu), 3.97-4.02 (m, 1H, CH-G), 4.48 (d, 2H, J = 5.70 Hz, PhCH₂OH), 5.15 (t, 1H, OH), 7.03 (d, 2H, J = 8.39 Hz, H_{arom3+5}), 7.31 (d, 2H, H_{arom2+6}), 8.04 (d, 1H, J = 7.88 Hz, NH-Ph), 9.98 (s, 1H, CHO); anal: (C₂₁H₃₁NO₇). C, H, N.

Example 12.

15 di-t-butyl,(4-benzaldehyde)oxycarbonyl-L-glutamate (13a).

To a solution of di-t-butyl-glutamyl isocyanate 6a [prepared from di-t-butyl-glutamate hydrochloride (0.200 g, 0.67 mmol), triphosgene (0.067 g, 0.22 mmol) and triethylamine (0.190 mL, 1.35 mmol) as above] in 15 mL CHCl₃, were added 4-hydroxybenzaldehyde (0.082 g, 0.67 mmol) and triethylamine (0.190 mL, 1.35 mmol) in 10 mL CHCl₃ over 10 20 min. The reaction was heated under reflux for 2 h, then the solvent was removed under vacuum. The compound was purified by preparative HPLC (eluent: cyclohexane:AcOEt 6:1). Finally a clear oil was obtained (0.197 g, 72%).

Example 13.

diallyl,(4-hydroxybenzyl)oxycarbonyl-L-glutamate (14b)

25 A clear solution of diallyl-glutamyl isocyanate 6b [prepared from diallyl-glutamate p-toluene sulphonate (3.28 g, 8.20 mmol), triphosgene (0.81 g, 2.73 mmol) and triethylamine (3.44 mL, 24.6 mmol) in 50 mL THF, at -78 °C, according to the procedure described above] was obtained by filtering the reaction mixture at room temperature. 4-hydroxybenzyl alcohol 29 (1.00 g, 8.10 mmol) was dissolved in THF (dry) (10 mL) and 18-crown-6 ether (0.20 mL) 30 and potassium tert-butoxide (0.16 g, 1.4 mmol) were added. To this mixture, the solution of isocyanate 6b was added dropwise at room temperature with vigorous stirring. The reaction

was terminated by addition of AcOH (0.5 mL). The reaction mixture was filtered and the solvent removed under vacuum. The residue was dissolved in AcOEt (20 mL), the solution washed with aqueous NaOH 4% (20 mL), with H₂O (2x20 mL), dried and evaporated to dryness. Compound 14b (1.62g, 53 %) resulted and was purified by preparative HPLC (eluent cyclohexane:AcOEt 1:1). Finally a clear oil was obtained (0.80 g, 26.5%). ¹H-NMR. δ_H: 1.90-2.01 (m, 1H, CH₂CH(NH)-), 2.05-2.09 (m, 1H, -CH₂CH(NH)-), 2.50-2.56 (m, 2H, CH₂CO₂A), 3.96-4.05 (m, 1H, -CH(NH)-), 4.48 (d, 2H, J=5.67 Hz, PhCH₂OH), 4.58 (d, 2H, J=5.26 Hz, CH₂O allyl), 4.63 (d, 2H, CH₂O allyl), 5.16 (t, 1H, OH), 5.19-5.38 (m, 4H, CH₂= allyl), 5.95-5.99 (m, 2H, CH= allyl), 7.04 (d, 2H, J=8.47 Hz, H_{arom3+5}), 7.32 (d, 2H, H_{arom2+6}), 8.24 (d, 1H, J=7.82 Hz, NH-Ph); MS, (FAB), (377,); m/z: 400 (M⁺+23, 82), 378 (M⁺+1, 3); accurate mass (C₁₉H₂₃NO₂Na): calc. 400.1372; found 400.1376

Example 14.

di-t-butyl,[4(4'nitrophenyloxycarbonyl)oxybenzyl]-oxycarbonyl-L-glutamate (15a)


Activation of linker 14a (1.0 g, 2.7 mmol) was achieved by the same procedure as in Example 9. After purification, an oil resulted (0.64 g, 41%). ν_{max}/cm⁻¹ (film): 3367 (NH₂), 2980, 2933 (CH₂, asym., sym.), 1767 (C=O, carbonate), 1728 (C=O, ester); ¹H-NMR, δ_H: 1.41 (s, 9H, t-Bu), 1.43 (s, 9H, t-Bu), 1.89-1.94 (m, 1H, CH₂CH(NH)-), 1.96-2.03 (m, 1H, CH₂CH(NH)-), 2.31-2.37 (m, 2H, CH₂CO₂-t-Bu), 3.96-4.05 (m, 1H, CH(NH)-), 5.30 (s, 2H, CH₂Ph), 7.15 (d, 2H, J = 8.46 Hz, H_{arom3+5}), 7.49 (d, 2H, H_{arom2+6}), 7.83 (d, 2H, J = 9.17 Hz, H_{arom3+5}), 8.12 (d, 1H, J=7.83 Hz, NH-Ph); 8.31 (d, 2H, H_{arom2+6}); MS, (FAB), (574, 50); m/z : 597 (M⁺+23, 12), 575 (M⁺+1, 4), 519 (M - t-Bu - 1, 10), 463 (M - 2t-Bu - 2, 4);

diallyl,[4(4'nitrophenyloxycarbonyl)oxybenzyl]-oxycarbonyl-L-glutamate (15b)

Starting from 14b (0.4 g, 1.06 mmol), 15b was obtained by a similar procedure. Purification yielded an oil (0.448g, 75.5%). ¹H-NMR, δ_H: 1.80-2.01 (m, 1H, CH(NH)CH₂-), 2.03-2.09 (m, 1H CH(NH)CH₂), 2.50-2.55 (m, 2H, CH₂CO₂A), 4.16-4.24 (m, 1H, CH(NH)-), 4.59 (d, 2H, J=5.29 Hz, CH₂O allyl), 4.63 (d, 2H, CH₂O allyl), 5.19-5.38 (m, 4H, CH₂= allyl), 5.31 (s, 2H, PhCH₂), 5.90-5.98 (m, 2H, CH= allyl), 7.16 (d, 2H, J=8.43 Hz, H_{arom3+5}), 7.50 (d, 2H, H_{arom2+6}), 7.58 (d, 2H, H_{arom3+5}), 8.11 (d, 2H, H_{arom2+6}); MS, (FAB), (542, 50); m/z: 563(M⁺+23, 10), accurate mass: calcd. (C₂₆H₂₆N₂O₁₁Na), 565.1434; found 565.1430.

CLAIMS

1. A compound of the formula (I):



wherein X and Y are independently chlorine, bromine, iodine, a mesyl group CH₃SO₃, or a tosyl group OSO₂phenyl (wherein phenyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from C₁₋₄alkyl, halogen, cyano or nitro;

n is an integer from 0 to 4 and each group R¹, which may be the same or different when n is greater than 1, is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C₁₋₄alkyl optionally containing one double bond or one triple bond, C₁₋₄alkoxy, -CONR⁷R⁸ (wherein R⁷ and R⁸ are as defined below), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)₂ or C₂₋₅ alkanoyl; or when n is 2 or more and two groups R¹ are on adjacent positions on the phenylene ring, 2 adjacent R¹ groups together represent

a) C₄ alkylene optionally having one double bond;

b) C₃ alkylene; or

c) -CH=CH-CH=CH-, -CH=CH-CH=CH₂ or -CH₂-CH=CH- each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy, halogen, cyano, nitro, C₂₋₅ alkanoyl and -CONR⁷R⁸ (wherein R⁷ and R⁸ are as defined below);

m is an integer from 0 to 4 and R², which may be the same or different when m is greater than 1, is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C₁₋₄alkyl optionally containing one double bond or one triple bond, C₁₋₄alkoxy, -CONR⁷R⁸ (wherein R⁷ and R⁸ are as defined below), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)₂ and C₂₋₅ alkanoyl; or when n is 2 or more and two groups R¹ are on adjacent positions on the phenylene ring, 2 adjacent R¹ groups together represent

a) C₄ alkylene optionally having one double bond;

b) C₃ alkylene; or

c) -CH=CH-CH=CH-, -CH=CH-CH₂- or -CH₂-CH=CH- each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, cyano, nitro, C₁₋₃ alkanoyl and -CONR₇R₈ (wherein R₇ and R₈ are as defined below);

Z¹ and Z² are each independently -O- or -NH-;

R³ hydrogen, β -butyl or allyl;

Z³ is a group -V-W where V is -CH₂-T- in which T is -CH₂-, -O-, -S-, -(SO)- or -(SO₂)- (provided that when V has sulphur or oxygen as its second atom, W is other than -CCOH) and said group V optionally further carrying one or two substituents Q¹ and/or Q² on carbon: wherein Q¹ and Q² each independently represents C₁₋₄ alkyl or halogen; or, when Q¹ and Q² are bonded to adjacent carbon atoms, Q¹ and Q² together may additionally represent a C₃-C₄ alkylene radical optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of C₁₋₄ alkyl and halogen. and W represents

(1) COOH.

(2) -(C=O)-O-R₆ wherein R₆ represents a C₁₋₆ alkyl, C₃₋₆ cycloalkyl or aryl (as defined in 3 below) group;

(3) -(C=O)-NR₇R₈ wherein R₇ and R₈ each independently represent hydrogen or a C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl linked to N via carbon or C₇₋₉ aralkyl group wherein aryl is phenyl;
heteroaryl is a 5 or 6 membered ring containing 1 to 3 heteroatoms selected from the group consisting of nitrogen and sulphur;
the aryl moiety *per se*, the heteroaryl moiety and the aryl moiety of the aralkyl group may be substituted on carbon with 1-4 substituents selected from the group consisting of -COOH, -OH, -NH₂, -CH₂-NH₂, -(CH₂)₁₋₄-COOH, tetrazol-5-yl and -SO₃H and the alkyl moiety may optionally carry a methyl group;

(4) -SO₂NHR₉ wherein R₉ is as defined for R₇ but may additionally represent -CF₃, -CH₂CF₃ or aryl as defined above;

(5) SO₂R₁₀ in which R₁₀ represents H, C₁₋₆ alkyl or C₃₋₆ cycloalkyl,

(6) $\text{PO}_2\text{R}10\text{R}10$ (wherein the R10 radicals, which may be the same or different, are as herein defined)

(7) a tetrazol-5-yl group;

(8) $-\text{CONH-SO}_2\text{R}11$ in which R11 represents

- C_{1-7} cycloalkyl;
- C_{1-6} -alkyl optionally substituted with substituents selected from the group consisting of aryl as defined below, C_{1-4} -alkyl, CF_3 , or halogen; and
- perfluoro- C_{1-6} alkyl; wherein


aryl is phenyl or phenyl having 1-5 substituents wherein the substituents are selected from the group consisting of halogen, $-\text{NO}_2$, $-\text{CF}_3$, C_{1-4} alkyl, C_{1-4} alkoxy, $-\text{NH}_2$, $-\text{NHCOPH}_3$, $-\text{CONH}_2$, $-\text{OCH}_2\text{COOH}$, $-\text{NH}(\text{C}_{1-4}\text{-alkyl})$, $-\text{N}(\text{C}_{1-4}\text{-alkyl})_2$, $-\text{NHCOC}_{1-4}\text{ alkyl}$, $-\text{OH}$, $-\text{COOH}$, $-\text{CN}$ and $-\text{COOC}_{1-4}\text{ alkyl}$; and

(9) $-\text{M-Het}$ wherein M represents S, SO or SO_2 , and Het represents a 5 or 6 membered heterocyclic aromatic ring linked to M via a carbon atom of the aromatic ring, said aromatic ring containing 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, N and S said aromatic ring optionally being substituted on carbon atoms of the ring with 1, 2, 3 or 4 substituents selected from the group consisting of $-\text{OH}$, $-\text{SH}$, $-\text{CN}$, $-\text{CF}_3$, NH_2 and halogen;

and physiologically acceptable derivatives of the compound of formula (I).

2. A compound according to claim 1 wherein R₁ and R₂ are each independently selected from hydrogen and fluorine, R₃ is hydrogen and Z³ is a group $\text{CH}_2\text{CH}_2\text{COOH}$.


3. A compound of the formula (II):



wherein X, Y, R¹, n, Z¹, R² and m are as defined in claim 1, and physiologically acceptable derivatives thereof.


4. A compound according to claim 3 wherein R¹ and R² are each independently selected from hydrogen and fluorine.
5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 together with one or more pharmaceutically acceptable carriers or diluents.
6. 4'-[N,N-bis(2-chloroethyl)amino]phenyloxycarbonyl-oxy-benzyl-4-carbamoyl-L-glutamic acid.
7. 4'-[N,N-bis(2-chloroethyl)amino]phenyloxycarbonyl-oxy-benzyl-4-oxycarbonyl-L-glutamic.
8. 4'-[N,N-bis(2-chloroethyl)amino]phenylcarbamoyloxy-benzyl-4-oxycarbonyl-L-glutamic acid.
9. 4'[N,N-bis(2-chloroethyl)amino]phenylcarbamoyloxy-benzyl-4-carbamoyl-L-glutamic acid.
10. Use of a compound according to any one of claims 1 to 9 in a method of treatment or therapy of the human or animal body.
11. A two component system for use in the control of neoplasia in a human or animal subject which comprises a compound according to any one of claims 1 to 9 and a vector or other delivery system capable of selectively infecting tumour cells in said subject, said vector carrying a DNA or RNA sequence encoding an enzyme capable of converting said compound to a nitrogen mustard active against said tumour.

12. A compound of the formula (IV):




where R^2 , m , Z^2 , R^3 and Z^3 are as defined in claim 1, and Q is a leaving group, with the proviso that when R^2 is fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, and C_{2-4} haloalkenyl, R^3 is hydrogen or a C_{1-6} alkyl group, and Z^3 is a group $-CH_2CH_2COOX^{10}$ where X^{10} is hydrogen or a C_{1-6} alkyl group, then Q is not a N -succinimidyl group.


13. A process for the production of a compound of formula (I) as defined in claim 1 which comprises reacting a compound of the formula (III):



in which X , Y , R^1 and n are as defined for formula (I) and Z^4 is $-O-$ or $-NH-$ with a compound of formula (IV)




in which R^2 , m , Z^2 , Z^3 and R^3 are as defined above, and Q is a leaving group or with a compound of formula (V):



in which R^2 , m , Z^2 , Z^3 and R^3 are as defined above, and recovering the compound of formula (I) produced.

14. A process for the production of a compound of formula (II) as defined in claim 3 which comprises reacting a compound of formula (III) as defined in claim 13 with 4-nitrobenzyl chloroformate optionally substituted with from 1 to 4 group(s) R^2 as defined in claim 3, and recovering the compound of formula (II) produced.

15. A compound of formula (V)



wherein R², m, Z², R³ and Z³ are as defined in claim 1.

Fig.1.




Fig.2.





Fig. 3.



According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 540 263 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD.) 5 May 1993 see claims; examples 8,9 ---	3,4,10, 11
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 21, 14 October 1994, WASHINGTON DC, US, pages 3452-8, XP002000756 A. B. MAUGER ET. AL.: "Self-Immulative Prodrugs. Candidates for Antibody-Directed Enzyme Prodrug Therapy in Conjunction with a Nitroreductase Enzyme." see whole document ---	3,4,10, 11,14
Y	WO,A,94 02450 (ZENECA LTD) 3 February 1994 cited in the application see claims; examples --- -/-	1,2,5-11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

1

Date of the actual completion of the international search

17 April 1996

Date of mailing of the international search report

24.06.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+ 31-70) 340-3016

Authorized officer

i.M.Helps
Helps, I

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>FR,A,1 463 764 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) 21 November 1966 see whole document</p> <p>---</p> <p>WO,A,88 07378 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD.) 6 October 1988 cited in the application see whole document</p> <p>-----</p>	1,2,5-11
Y		1,2,5-11

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-540263	05-05-93	AU-B-	2776992	21-05-93
		EP-A-	0638123	15-02-95
		WO-A-	9308288	29-04-93
		JP-T-	7501692	23-02-95
-----	-----	-----	-----	-----
WO-A-9402450	03-02-94	AU-B-	4715693	14-02-94
		CA-A-	2101104	24-01-94
		CZ-A-	9500151	15-11-95
		EP-A-	0651740	10-05-95
		FI-A-	950230	19-01-95
		HU-A-	69288	28-09-95
		JP-T-	7509461	19-10-95
		NO-A-	950210	23-01-95
		PL-A-	307226	15-05-95
		SK-A-	6995	11-07-95
		US-A-	5405990	11-04-95
		ZA-A-	9305290	26-04-94
		ZW-A-	9293	30-03-94
-----	-----	-----	-----	-----
FR-A-1463764	09-03-67	NONE		-----
-----	-----	-----	-----	-----
WO-A-8807378	06-10-88	DE-D-	3889340	01-06-94
		DE-T-	3889340	01-09-94
		EP-A-	0408546	23-01-91
-----	-----	-----	-----	-----